AndroGel Buyer Seeks 2nd Shot At Pay-For-Delay Suit
An indirect purchaser of Solvay Pharmaceuticals Inc.'s testosterone supplement AndroGel has asked for leave to amend a recently dismissed putative class action accusing the drugmaker of keeping generics rivals out of...To view the full article, register now.
Already a subscriber? Click here to view full article